Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy

Abstract

BackgroundNeutron capture therapy for glioblastoma has focused mainly on the use of 10B as neutron capture isotope. However, 157Gd offers several advantages over boron, such as higher cross section for thermal neutrons and the possibility to perform magnetic resonance imaging during neutron irradiation, thereby combining therapy and diagnostics. We have developed different liposomal formulations of gadolinium-DTPA (Magnevist®) for application in neutron capture therapy of glioblastoma. The formulations were characterized physicochemically and tested in vitro in a glioma cell model for their effectiveness.MethodsLiposomes entrapping gadolinium-DTPA as neutron capture agent were manufactured via lipid/film-extrusion method and characterized with regard to size, entrapment efficiency and in vitro release. For neutron irradiation, F98 and LN229 glioma cells were incubated with the newly developed liposomes and subsequently irradiated at the thermal column of the TRIGA reactor in Mainz. The dose rate derived from neutron irradiation with 157Gd as neutron capturing agent was calculated via Monte Carlo simulations and set in relation to the respective cell survival.ResultsThe liposomal Gd-DTPA reduced cell survival of F98 and LN229 cells significantly. Differences in liposomal composition of the formulations led to distinctly different outcome in cell survival. The amount of cellular Gd was not at all times proportional to cell survival, indicating that intracellular deposition of formulated Gd has a major influence on cell survival. The majority of the dose contribution arises from photon cross irradiation compared to a very small Gd-related dose.ConclusionsLiposomal gadolinium formulations represent a promising approach for neutron capture therapy of glioblastoma cells. The liposome composition determines the uptake and the survival of cells following radiation, presumably due to different uptake pathways of liposomes and intracellular deposition of gadolinium-DTPA. Due to the small range of the Auger and conversion electrons produced in 157Gd capture, the proximity of Gd-atoms to cellular DNA is a crucial factor for infliction of lethal damage. Furthermore, Gd-containing liposomes may be used as MRI contrast agents for diagnostic purposes and surveillance of tumor targeting, thus enabling a theranostic approach for tumor therapy.

Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design

“…Although in the present work the endocytic mechanisms were not investigated, we speculate that the difference in the extent of internalisation between the free prodrug and the pH-sensitive liposomes could rely on the involvement of distinct uptake modalities and/or kinetics of intracellular processing. There is compelling evidence showing that liposome/nanoparticle uptake is influenced by a multitude of parameters, including nanocarrier size 52,54 , surface charge 55,56 and hydrophobicity 56,57 , lipid composition 58,59 , shape 53,56 and cell type 53,54 .…”

Synthesis, Characterization, and Enhanced Cancer‐Imaging Application of Trans‐activator of Transcription Peptide‐conjugated Ultrasmall Gadolinium Oxide Nanoparticles

“…Gadolinium oxide (Gd 2 O 3 ) nanoparticles (GNPs) are extremely useful for biomedical applications because they possess various excellent physical properties applicable to cancer theragnosis . These applications include positive (T 1 ) magnetic resonance imaging (T 1 MRI), computed tomography (CT) scan, and gadolinium neutron capture therapy (GdNCT) of cancers . For biomedical applications, coating of the GNP surfaces with hydrophilic and biocompatible ligands is essential.…”

Targeting glioma stem cells enhances anti-tumor effect of boron neutron capture therapy

“…However, successful BNCT requires selective targeting and delivery of adequate 10 B to all tumor cells (∼ 20 μg/g weight or ∼10 9 atoms/cell). Previous studies confirmed 10 B uptake by proliferative cells targeted for killing with thermal neutrons [4–6]. …”